Micafungin is an echinocandin-class antifungal agent licensed for treatment of invasive disease in adults. The optimal dosing regimens have not been established for infants. We describe a premature infant who developed hepatitis and cholestasis during micafungin therapy initiated for protracted candidemia. Practitioners should be aware of this potential adverse effect if using micafungin in young patients.
Introduction
Optimal treatment of invasive fungal infection is an ongoing challenge for neonatologists, especially as the number of immunosuppressed and premature patients increases. Micafungin is a member of the echinocandin family of antifungals recently licensed for adults as an alternative or complement to traditional agents such as azoles and amphotericin B. 1 Optimal dosing and safety of this agent have not been established for infants and children.
Case report A 44-day-old 2400 g former 28 week human immunodeficiency virus (HIV) and hepatitis C-exposed premature female was in her fourth week of nafcillin therapy for methicillin-susceptible Staphylococcus aureus bacteremia and right femoral osteomyelitis when she developed a new illness manifested as apnea requiring bag-mask ventilation. Blood, urine and cerebrospinal fluid (CSF) cultures were sent, and empirical treatment was initiated with vancomycin and gentamicin. After 1 day, her blood culture grew Candida albicans. The CSF and urine cultures were sterile. Therapy was changed to conventional amphotericin B (1 mg kg À1 per day) and her peripherally inserted central catheter (PICC) was removed. Head and renal ultrasounds were obtained and were normal. An echocardiogram showed a linear echodensity in the left innominate vein consistent with a cast at the location of the previous PICC line, and an ophthalmologic examination showed lesions consistent with Candida in the superior macula of the retina.
Candidemia persisted, and on the seventh day of amphotericin B therapy, micafungin was added to the regimen at a dose of 8 mg kg À1 daily. The dose was chosen based on preliminary pharmacokinetic work by Heresi et al. 1 and expert opinion. Blood cultures became sterile 3 days later, and an ophthalmologic exam on day 7 of micafungin showed improvement in the retinal lesions.
Before initiation of micafungin, the patient's serum aspartate aminotransaminase (AST) was 21 IU l À1 , serum alanine aminotransaminase (ALT) was 20 IU l À1 , total bilirubin was 1 mg per 100 ml and alkaline phosphatase was 268 IU l À1 . On day 2 of micafungin administration, the total bilirubin was 11.7 mg per 100 ml with direct bilirubin of 10.1 mg per 100 ml, but the AST and ALT were 25 and 28 IU l À1 , respectively ( Figure 1 ). On day 8 of micafungin administration, the AST had increased to 79 IU l À1 and the ALT to 39 IU l À1 . The total bilirubin was 12 mg per 100 ml and the conjugated bilirubin was 8.3 mg per 100 ml. The patient was transferred to our care on day 14 of micafungin treatment. On day 16, the AST was 377 IU l À1 and the ALT 850 IU l À1 , with a total bilirubin of 16.3 mg per 100 ml and conjugated bilirubin of 12 mg per 100 ml. The partial thromboplastin time was elevated at 40.2 s, prothrombin time was 12.7 s and the international normalized ratio was 1.2. On the basis of this degree of hepatic dysfunction, micafungin was discontinued.
The patient had received azidothymidine for the first 6 weeks of her life and she was receiving trimethoprim/sulfamethoxazole prophylaxis 3 days per week. She had received total parenteral nutrition intermittently for the first 6 weeks of life, but her peak alkaline phosphatase was 506 IU l À1 and direct bilirubin was 3.6 mg per 100 ml on the last day of total parenteral nutrition, 9 days before the Candida infection.
To investigate other potential causes of hepatitis and cholestasis, a urine culture for cytomegalovirus, PCR test for Hepatitis C and HIV at 1 and 6 months, a-1-antitrpysin level, and abdominal ultrasound were performed and all of these tests were negative. At 4 days after the discontinuation of micafungin and without other changes in her medications, the infant's AST was 427 IU l À1 and the ALT was 690 IU l À1 . The elevation in hepatic transaminases and total bilirubin gradually declined as shown in Figure 1 .
Discussion
Micafungin is an inhibitor of 1, 3-b-D-glucan synthase, and it is the second echinocandin class antifungal agent licensed for adults in the United States. 2 The drug is cleared by hepatic P450 and non-P450 metabolic pathways. A double-blind noninferiority trial of adults with candidemia and invasive candidiasis indicated similar efficacy and fewer metabolic and administration-associated side effects when comparing micafungin to amphotericin B. 3 Micafungin has only been licensed for adults. Optimal dosing, safety and efficacy have not been studied extensively in children. One pharmacokinetic and safety study of 77 febrile neutropenic children ranging in age from 2 to 17 years showed minimal toxicity at a dose range of 0.5 to 4 mg kg À1 , with two patients showing modest increases in hepatic transaminases and one experiencing a mild elevation in bilirubin. 4 Heresi et al. 1 addressed the pharmacokinetics and safety of micafungin use in 18 premature neonates averaging 31 weeks post-conceptual age after a single dose of micafungin at 0.75, 1.5 or 3 mg kg À1 . The drug was cleared at a faster rate from children compared with adults, and the authors estimated that a dose of 5 to 7 mg kg À1 for premature neonates over 1000 g would lead to serum drug exposure equivalent to an adult dose of 100 to 150 mg. A population model of micafungin pharmacokinetics also found that higher doses are required in smaller children to achieve drug levels comparable to those found in adults. 5 No significant drug-related toxicity has, to our knowledge, previously been reported at the dosages of micafungin used in children, and animal data indicate that toxicities in mice are not observed below a dose of 32 mg kg À1 . 4 The product label does note that 5.4% of patients in a safety study experienced elevation in the alanine transaminase level. 6 In addition, the European Medicines Agency states in its assessment report that use of micafungin may lead to liver tumors, and that it should 'only be used if other antifungals are not appropriate'. 7 An investigation in adults to explore the maximum tolerated dose in hematopoietic stem cell transplant recipients indicated no significant toxicity for micafungin dosages up to 8 mg kg
À1
for a mean of 20 days, although one patient did demonstrate elevated bilirubin at the 8 mg kg À1 dose. 8 Our patient experienced elevation of hepatic transaminases and bilirubin in association with use of micafungin at a dose of 8 mg kg À1 per day. It is possible that preceding hepatic stressors contributed to her reaction to micafungin. Indeed, the direct bilirubin was modestly elevated several days before initiation of micafungin. However, the temporal relationship to micafungin administration and the improvement of hepatic function upon its discontinuation suggest strongly that hepatotoxicity was micafungin induced in our patient.
Our patient's protracted candidemia did resolve while she was receiving micafungin in addition to amphotericin B. It is not possible to determine the direct contribution of micafungin to resolution of the fungemia. A success rate of 83% in clearing candidal blood stream infections has been described using micafungin alone in 126 patients that included 20 children. 9 Our patient illustrates that substantial hepatotoxicity can be observed in association with administration of micafungin at a dose of 8 mg kg À1 daily in a premature infant. Further studies are needed to gain knowledge about the pharmacokinetics, pharmacodynamics, safety and efficacy of this drug in the pediatric population. We urge practitioners to use caution and to monitor hepatic function closely when choosing to use this promising new drug. Figure 1 Alanine aminotransaminase levels and total serum bilirubin became elevated during micafungin treatment and declined gradually after discontinuation of the drug. The shaded area indicates the 16-day interval of micafungin administration.
